ReviewJournal of clinical biochemistry and nutrition2020

Epigallocatechin-3-gallate (EGCG) attenuates non-alcoholic fatty liver disease via modulating the interaction between gut microbiota and bile acids.

Yuji Naito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.